S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:ABEO

Abeona Therapeutics Stock Forecast, Price & News

$0.57
-0.03 (-4.96%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.56
$0.62
50-Day Range
$0.58
$1.18
52-Week Range
$0.56
$3.79
Volume
910,090 shs
Average Volume
980,896 shs
Market Capitalization
$58.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.43
30 days | 90 days | 365 days | Advanced Chart
Receive ABEO News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Abeona Therapeutics logo

About Abeona Therapeutics

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$10 million
Book Value
$0.78 per share

Profitability

Net Income
$-84.23 million
Pretax Margin
-1,802.70%

Debt

Price-To-Earnings

Miscellaneous

Free Float
86,223,000
Market Cap
$58.60 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/23/2022

MarketRank

Overall MarketRank

2.24 out of 5 stars

Medical Sector

353rd out of 1,390 stocks

Pharmaceutical Preparations Industry

154th out of 668 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -












Abeona Therapeutics (NASDAQ:ABEO) Frequently Asked Questions

Is Abeona Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Abeona Therapeutics stock.
View analyst ratings for Abeona Therapeutics
or view top-rated stocks.

How has Abeona Therapeutics' stock been impacted by Coronavirus?

Abeona Therapeutics' stock was trading at $2.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ABEO shares have decreased by 73.7% and is now trading at $0.5750.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Abeona Therapeutics?

Abeona Therapeutics saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 2,110,000 shares, a decrease of 20.7% from the October 31st total of 2,660,000 shares. Based on an average daily trading volume, of 704,700 shares, the short-interest ratio is currently 3.0 days. Currently, 2.4% of the company's stock are short sold.
View Abeona Therapeutics' Short Interest
.

When is Abeona Therapeutics' next earnings date?

Abeona Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Abeona Therapeutics
.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) released its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.16).
View Abeona Therapeutics' earnings history
.

What price target have analysts set for ABEO?

3 brokerages have issued 1 year target prices for Abeona Therapeutics' shares. Their forecasts range from $1.00 to $4.00. On average, they expect Abeona Therapeutics' share price to reach $2.50 in the next year. This suggests a possible upside of 334.8% from the stock's current price.
View analysts' price targets for Abeona Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the following people:
  • Mr. Steven H. Rouhandeh, Exec. Chairman (Age 61)
  • Dr. Timothy J. Miller, Pres, Chief Scientific Officer & Director (Age 46)
  • Mr. Jeffrey Blaine Davis, Chief Operating Officer (Age 55)
  • Mr. Carsten Thiel, Chief Exec. Officer (Age 54)
  • Mr. Stephen B. Thompson, Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer (Age 64)

What other stocks do shareholders of Abeona Therapeutics own?

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.61%), Morgan Stanley (1.32%), Geode Capital Management LLC (0.81%), Millennium Management LLC (0.68%), Franklin Resources Inc. (0.32%) and Assenagon Asset Management S.A. (0.32%). Company insiders that own Abeona Therapeutics stock include Brendan M O'malley, Edward Carr, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc, Stefano Buono and Todd Wider.
View institutional ownership trends for Abeona Therapeutics
.

Which major investors are selling Abeona Therapeutics stock?

ABEO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morgan Stanley, Goldman Sachs Group Inc., Citadel Advisors LLC, BlackRock Inc., and Dimensional Fund Advisors LP. Company insiders that have sold Abeona Therapeutics company stock in the last year include Brendan M O'malley, Edward Carr, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc, and Todd Wider.
View insider buying and selling activity for Abeona Therapeutics
or view top insider-selling stocks.

Which major investors are buying Abeona Therapeutics stock?

ABEO stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., ACT Capital L.L.C., Assenagon Asset Management S.A., Geode Capital Management LLC, and GSA Capital Partners LLP.
View insider buying and selling activity for Abeona Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $0.58.

How much money does Abeona Therapeutics make?

Abeona Therapeutics has a market capitalization of $58.60 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-84.23 million in net income (profit) each year or ($0.57) on an earnings per share basis.

What is Abeona Therapeutics' official website?

The official website for Abeona Therapeutics is www.abeonatherapeutics.com.

Where are Abeona Therapeutics' headquarters?

Abeona Therapeutics is headquartered at 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at [email protected], or via fax at 214-905-5101.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.